Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

By Chim C.  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 181-182

Springer Publishing Company

Access to resources Recommend Favorite

Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy

By Musolino Caterina   Alonci Andrea   Catena Sara   Rizzotti Patricia   Russo Sabina   Rotondo Francesco   Allegra Alessandro  

Acta Oncologica, Vol. 52, Iss. 5, 2013-06 ,pp. : 1050-1051

Informa Healthcare

Access to resources Recommend Favorite

Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma

By          

Oncology Letters, Vol. 10, Iss. 2, 2015-01 ,pp. : 1171-1175

Spandidos Publications

Access to resources Recommend Favorite

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration

By Terpos Evangelos   Politou Marianna   Rahemtulla Amin  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 10, 2004-10 ,pp. : 623-625

Springer Publishing Company

Access to resources Recommend Favorite

Astrocytoma development following complete multiple myeloma remission in a 49yearold patient: A case report

By Han Xiaoyan   Jin Dian   Zheng Gaofeng   Luo Yi   Cai Zhen  

Experimental and Therapeutic Medicine, Vol. 6, Iss. 2, 2013-08 ,pp. : 509-512

Spandidos Publications

Access to resources Recommend Favorite